NIAID Centralized Sequencing Protocol
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03206099|
Recruitment Status : Recruiting
First Posted : July 2, 2017
Last Update Posted : July 29, 2022
Genetic testing called "sequencing" helps researchers look at DNA. Genes are made of DNA and are the instructions for our bodies to function. We all have thousands of genes. DNA variants are differences in genes between two people. We all have lots of variants. Most are harmless and some cause differences like blue or brown eyes. A few variants can cause health problems.
To understand the genetics of immune disorders various health conditions, as well as outcomes of clinical genomics and genetic counseling services performed under this protocol.
Participants in other NIH human subjects research protocols - either at the NIH Clinical Center (CC) or at Children s National Health System (CNHS) - (aged 0-99 years), and, in select cases, their biological relatives
Researchers will study participant s DNA extracted from blood, saliva, or another tissue sample, including previously collected samples we may have stored at the NIH. Researchers will look at participant s DNA in great detail. We are looking for differences in the DNA sequence or structure between participants and other people.
Participants will receive results that:
- Are important to their health
- Have been confirmed in a clinical lab
- Suggest that they could be at risk for serious disease that may affect your current or future medical management.
Some genetic information we return to participants may be of uncertain importance.
If genetic test results are unrelated to the participant s NIH evaluations, then we will not typically report:
- Normal variants
- Information about progressive, fatal conditions that have no effective treatment
- Carrier status (conditions you don t have but could pass on)
The samples and data will be saved for future research.
Personal data will be kept as private as possible.
If future studies need new information, participants may be contacted.
|Condition or disease|
|Atopy Primary Immunodeficiency Autoimmunity Autoinflammation|
|Study Type :||Observational|
|Estimated Enrollment :||10000 participants|
|Official Title:||NIAID Centralized Sequencing Protocol|
|Actual Study Start Date :||July 31, 2017|
|Estimated Primary Completion Date :||December 31, 2029|
|Estimated Study Completion Date :||December 31, 2029|
Biological relatives of probands, who may or may not also be co-enrolled on the proband's referring protocol.
Select internal controls
Participants with a disease under investigation by another NIAID protocol on which they are enrolled, either at the NIH or CNHS.
- Identifying novel genetic defects associated with immune disorders [ Time Frame: Upon analysis of genomic data ]Identifying novel genetic defects associated with immune disorders
- Identifying novel clinical phenotypes associated with established genetic defects [ Time Frame: Upon analysis of genomic data ]Identifying novel clinical phenotypes associated with established genetic defects
- Identifying established genetic disorders of the immune system [ Time Frame: Upon analysis of genomic data ]Identifying established genetic disorders of the immune system, as well as known genetic disorders outside of the immune system in some cases
- Evidence base for how to improve clinical genomic services on this protocol and related programs. [ Time Frame: 5.1.1. Enrollment/Baseline Report Comprehension Survey and Semi-Structured Phone Interviews ]Studies of the processes and outcomes of the clinical genomics and genetic counseling services performed under this protocol. These studies will use surveys, interviews, and other social and behavioral research methods to collect data from study participants about their perceptions, experiences, and attitudes related to their condition and participation in this protocol. The goal of these additional studies will be to improve the services provided under protocol 17-I-0122 and to generate an evidence base for other investigators conducting similar studies.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03206099
|Contact: Morgan N Similuk||(301) email@example.com|
|United States, District of Columbia|
|Children's National Health System||Recruiting|
|Washington, District of Columbia, United States, 20010|
|Contact: Vanessa Bundy 202-476-3016 firstname.lastname@example.org|
|United States, Maryland|
|National Institutes of Health Clinical Center||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY dial 711 email@example.com|
|Principal Investigator:||Morgan N Similuk||National Institute of Allergy and Infectious Diseases (NIAID)|